Savara(SVRA) Stock Price Today | Quotes & News

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

12 Health Care Stocks Moving In Tuesday's After-Market Session
BenzingaMar 18 17:05 ET
Savara Ro To Present Data For Phase 3 IMPALA-2 Trial Of Molgramostim Inhalation Solution At American Thoracic Society International Conference 2025
BenzingaMar 17 08:10 ET
Savara to Present New Data From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the American Thoracic Society International Conference 2025
Yahoo FinanceMar 17 08:05 ET
$SVRA Stock Is up 7% Today. Here's What We See in Our Data.
Quiver QuantitativeMar 13 11:30 ET
Savara's Innovative Testing and BLA Submission Drive Buy Rating Amid Market Growth Potential
TipRanksMar 6 11:06 ET · Ratings
Savara Launches Test for Autoimmune Lung Disease in US; Shares Up Pre-Bell
MT NewswiresMar 6 08:54 ET

Comments

Teddy123

Mar 6 21:06

Savara Announces U.S. Launch of the aPAP ClearPath™ Dried Blood Spot Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

$Savara (SVRA.US)$
Game-Changing Finger-Prick Test Could Transform Rare Lung Disease Diagnosis - What Makes It Special?

1

Teddy123

Jan 30 22:12

Savara Announces Manuscript on Long-Term Outcomes With Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Published in ERJ Open Research

$Savara (SVRA.US)$
Game-Changing Results: This Rare Disease Treatment Just Eliminated Need for Invasive Lung Procedures

Jaguar8

Jan 30 21:44

NEWS

$Savara (SVRA.US)$
Savara Announces Manuscript on Long-Term Outcomes With Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Published in ERJ Open Research
Savara Inc. (SVRA) announced the publication of a manuscript in ERJ Open Research detailing long-term outcomes of molgramostim inhalation solution in treating autoimmune pulmonary alveolar proteinosis (aPAP). The retrospective study evaluated five aPAP patients who received molgramostim thro...

1

Trytosaveabit

Jan 30 21:42

update

$Savara (SVRA.US)$ Savara Announces Manuscript on Long-Term Outcomes With Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Published in ERJ Open Research
2 MINUTES AGO, 8:39 AM EST
VIA BUSINESSWIRE
-- Real World, Retrospective Outcomes Data Suggest Molgramostim Addresses the Underlying Pathophysiology of aPAP Resulting in Improved Lung Function, Decreased Disease Burden, Restored Patient Functionality, and Reduction of Clinical Symptoms

Trytosaveabit

Dec 19, 2024 05:09

Update

$Savara (SVRA.US)$ Reuters· just
Savara Initiates Rolling Submission of a Biologics License Application (Bla) to the U.S. Food and Drug Administration (FDA) for Molbreevi* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (Apap)

2

SVRA Savara

Trade Overview

Capital Trend

News

Comments

Market Insights